滚动资讯
Merck KGaAMerck KGaA taps into Remepy’s Hybrid Drug platform - The Pharma LetterGE HealthCareGE HealthCare’s stock plunges 13% as supply chain costs bite - Medical Device NetworkBioPharma Dive默克仍看好Terns白血病药物的前景Merck & Co.Merck & Co lifts outlook as Keytruda growth offsets acquisition hit - The Pharma LetterCell蛋白质稳态维持T细胞分化潜能及肿瘤浸润淋巴细胞功能CellERDRP-0519对不同麻疹病毒属和亨尼帕病毒属聚合酶的差异抑制及基于结构的抑制剂优化BioPharma DiveUniQure取得“象征性”胜利，将寻求英国批准亨廷顿病基因疗法Merck & Co.Merck's growth products Winrevair, Ohtuvayre trending in opposite directions - Fierce PharmaEndpoints News阿瓦林扩大IPO规模；Alector终止与GSK合作的另一项研究Endpoints News分析师关注百时美施贵宝年度三大重点计划BioPharma Dive礼来再创佳绩，焦点转向Foundayo上市Endpoints NewsXTL生物收购迷幻生物技术公司；药明康德第一季度营收增长
暂时没有全文，请查看原始来源。